Rotator cuff injuries are among the most common — and most stubborn — musculoskeletal conditions in orthopaedic medicine. The rotator cuff is a group of four tendons that stabilise the shoulder joint and enable the full range of arm motion. When one or more of these tendons is torn or degenerated, the result is pain, weakness, and a shoulder that simply does not work the way it should. [1]

Where conventional treatment falls short. Standard care for rotator cuff tears follows a predictable ladder: rest, physiotherapy, corticosteroid injections, and — for full-thickness tears — surgical repair. While surgery can reattach the torn tendon to bone, the re-tear rate is sobering. Studies report failure rates of 20–94% depending on tear size, patient age, and tissue quality. The fundamental problem is biological: the tendon-to-bone insertion site (the enthesis) does not regenerate its original graded structure after repair. Instead, it heals with disorganised scar tissue that is mechanically weaker and prone to re-injury. [2][3]

The tissue-level challenge. The rotator cuff enthesis is a marvel of biological engineering — a continuous transition from flexible tendon to stiff bone across just a few hundred micrometres. This gradient is not reproduced by surgical repair or natural scarring. The result is a stress concentration at the repair site that predisposes to failure. Beyond the mechanical problem, rotator cuff tendons are intrinsically hypovascular, especially in the "critical zone" near the supraspinatus insertion, where most tears occur. This poor blood supply limits the delivery of the body's own repair cells and growth factors. [4]

MSC therapy targets the root cause. Mesenchymal Stem Cell therapy is being investigated not as a replacement for surgical repair when it is clearly indicated, but as a biological adjunct that may improve the quality of tendon-to-bone healing. By delivering a concentrated population of regenerative cells to the repair site, MSC therapy aims to shift the healing response from disorganised scar formation toward organised tissue regeneration — addressing the biological shortfall that makes rotator cuff repair so challenging. [5]

What is the rotator cuff and why does it tear?

The rotator cuff comprises four muscles and their tendons: the supraspinatus (abduction), infraspinatus and teres minor (external rotation), and subscapularis (internal rotation). Together, they form a cuff that centres the humeral head in the glenoid socket during arm movement. The supraspinatus tendon is the most frequently injured, accounting for the majority of tears, because it passes through a narrow subacromial space and bears significant mechanical load.

Tears are classified as partial-thickness (the tendon is frayed but not completely severed) or full-thickness (a complete discontinuity). Partial tears are further divided into articular-sided (on the joint side), bursal-sided (on the outer surface), and intrasubstance (within the tendon). Full-thickness tears are measured by the degree of tendon retraction — small (<1 cm), medium (1–3 cm), large (3–5 cm), and massive (>5 cm or involving two or more tendons). [6]

Risk factors include age (tears are present in >50% of individuals over 60), repetitive overhead activity (swimmers, throwers, painters), acute trauma (falls, heavy lifting), and smoking — which impairs tendon vascularity. Degenerative tears accumulate slowly over years as the tendon undergoes mucoid degeneration, fatty infiltration, and loss of organised collagen structure.

Scientific illustration of the four rotator cuff tendons showing cellular regeneration at a partial tear site
The four rotator cuff tendons converge around the humeral head. MSC therapy is being studied for its ability to support biological healing at the tendon-bone interface — the most challenging site in orthopaedic repair.

How MSC therapy supports rotator cuff healing

When Mesenchymal Stem Cells are delivered to the site of a rotator cuff tear — whether by direct injection under ultrasound guidance, or as an adjunct applied during arthroscopic repair — they engage the local environment through several coordinated mechanisms that are directly relevant to the biology of tendon-to-bone healing:

1. Modulation of the inflammatory environment

After a rotator cuff tear, the injured tendon and surrounding bursa enter a chronic inflammatory state characterised by elevated levels of IL-1β, IL-6, and TNF-α. While acute inflammation is necessary for the initial healing cascade, persistent inflammation drives matrix breakdown, inhibits tenocyte function, and promotes fatty infiltration of the muscle belly — a process that is essentially irreversible once established. MSCs respond to this high-cytokine environment by secreting anti-inflammatory mediators — TSG-6, PGE2, and IDO — that help shift the injury site from catabolic breakdown toward anabolic repair. [7]

2. Promotion of enthesis regeneration

The holy grail of rotator cuff repair is regeneration of the native enthesis — the four-zone transition from tendon (Zone I: collagen fibres) to fibrocartilage (Zone II) to mineralised fibrocartilage (Zone III) to bone (Zone IV). MSCs secrete a rich cocktail of growth factors — TGF-β3, BMP-2, and FGF-2 — that are known to be involved in enthesis development during embryogenesis. Preclinical studies in rat and rabbit rotator cuff models have shown that MSC-augmented repair results in a more organised fibrocartilage transition zone, with improved collagen fibre alignment and higher failure loads compared to repair alone. [8][9]

3. Reduction of post-surgical fibrosis and adhesion

One of the most clinically relevant complications of rotator cuff repair is post-operative stiffness caused by excessive scar tissue and subacromial adhesions. MSCs appear to influence the balance between regeneration and fibrosis through their effects on TGF-β1 signalling. By modulating the ratio of TGF-β1 (pro-fibrotic) to TGF-β3 (pro-regenerative), MSCs may help reduce the formation of disorganised scar and the adhesions that limit post-operative range of motion. [10]

4. Support for angiogenesis in the critical zone

The "critical zone" of the supraspinatus tendon — approximately 1 cm proximal to its insertion — is notoriously hypovascular, which is both a contributing factor to tear formation and a barrier to healing. MSCs secrete VEGF and other angiogenic factors that support the formation of new microvessels, improving oxygen and nutrient delivery to the healing tissue. This is particularly relevant in the early post-operative period when the repair site is dependent on diffusion from surrounding tissues.

What MSC therapy does NOT do for rotator cuff tears

It is essential to set honest expectations. MSC therapy does not close a retracted full-thickness tear — a tendon that has pulled away from its insertion by 3 cm requires surgical reapproximation. It does not replace the need for a structured rehabilitation programme — physiotherapy remains the cornerstone of recovery. It does not guarantee a return to pre-injury function, particularly in long-standing tears with significant muscle atrophy and fatty infiltration. What the evidence suggests it may do is improve the quality of healing at the cellular level, potentially reducing re-tear rates and improving functional outcomes — particularly in patients with poor native healing capacity.

Clinical evidence for MSC therapy in rotator cuff repair

The clinical evidence base for MSC therapy in rotator cuff disease is growing but still early-stage. Most published studies are small (n = 10–50), with follow-up periods of 1–3 years. The majority have investigated MSC augmentation of arthroscopic repair rather than stand-alone injection therapy. Here is a summary of the key findings:

MSC-augmented arthroscopic repair

Several prospective studies have compared arthroscopic rotator cuff repair with and without MSC augmentation. A 2020 randomised controlled trial of 30 patients with full-thickness supraspinatus tears reported that the MSC-augmented group had significantly lower re-tear rates at 12 months on MRI (13% vs. 40% in the control group, p < 0.05) and superior functional scores (ASES, Constant). [11]

A 2022 systematic review and meta-analysis of 7 studies (n = 327 patients) concluded that MSC augmentation was associated with a statistically significant reduction in re-tear rate (odds ratio 0.21, 95% CI 0.09–0.48) and improvement in the Constant-Murley score (mean difference 4.9 points, 95% CI 1.2–8.6) compared to repair alone. The authors noted that the quality of evidence was moderate and that larger, multicentre trials are needed. [12]

Injectable MSC therapy for partial tears

For partial-thickness tears — where the tendon is not completely detached and surgery may not be indicated — ultrasound-guided MSC injection is being explored as a less invasive option. A 2021 pilot study of 20 patients with high-grade partial-thickness supraspinatus tears (≥50% thickness) treated with a single ultrasound-guided injection of Wharton's jelly–derived MSCs reported significant improvements in VAS pain scores (from 7.2 to 2.1, p < 0.001) and ASES scores (from 48 to 82, p < 0.001) at 12 months. MRI demonstrated a reduction in tear size in 14 of 20 patients (70%). [13]

Key takeaway from the evidence

The current evidence suggests that MSC therapy is most promising in two clinical scenarios: (1) as an adjunct to arthroscopic repair of full-thickness tears, where the biological boost may reduce re-tear rates, and (2) as a standalone injection for partial-thickness tears in patients who wish to avoid or delay surgery. The evidence is not yet sufficient to recommend MSC therapy as a replacement for surgical repair of large or retracted tears.

Who is a candidate for MSC rotator cuff therapy?

Not every patient with a rotator cuff tear is a suitable candidate for MSC therapy. Clinical decision-making is individualised and based on several factors:

Patients who may benefit most

Patients who are less suitable

Recovery timeline: what to expect after MSC therapy

Recovery after MSC therapy for a rotator cuff injury follows a structured, phased approach. The timeline depends on whether the MSCs are delivered as a standalone injection or as an adjunct to surgery:

Week 1–2

Inflammatory phase. The shoulder is rested in a sling. Mild post-injection soreness is normal. For surgical patients, this is the standard post-operative immobilisation period. The MSCs are responding to the local cytokine environment and beginning to secrete paracrine factors.

Week 2–6

Proliferative phase. Passive range-of-motion exercises begin under physiotherapist guidance. The cellular repair response is actively underway — growth factor signalling is at its peak, and the first new collagen is being laid down. For injection-only patients, daily activities can gradually resume, but overhead movements and lifting remain restricted.

Week 6–12

Remodelling phase. Active-assisted range of motion begins. Strengthening exercises are introduced gradually. The repair tissue is maturing, and collagen fibres are being organised along lines of mechanical stress. This is the phase where the quality of biological healing — versus simple scar formation — becomes apparent.

Month 3–6

Strengthening phase. Progressive resistance training. Return to sport-specific drills for athletes. For surgical patients, this is the phase where the biological advantage of MSC augmentation may translate into a more durable repair — but the tissue is not yet at full strength.

Month 6–12

Return to full activity. Full return to sport, overhead work, and recreational activities. MRI at this stage is used to assess the structural integrity of the repair. The re-tear rate — the key outcome measure — is typically assessed at 12 months.

Comparing MSC sources for rotator cuff therapy

Two main categories of MSCs are used in clinical practice for rotator cuff pathology:

Wharton's jelly–derived MSCs (allogeneic)

These are mesenchymal stem cells extracted from the Wharton's jelly of donated umbilical cord tissue. They are expanded under GMP conditions, characterised for identity and purity, and administered as an off-the-shelf product. Advantages for rotator cuff applications include: consistent potency (not dependent on patient age or health), strong immunomodulatory and anti-inflammatory properties, high proliferative capacity, and the avoidance of a second harvesting procedure. At a clinical-grade facility, these cells are validated to ≥95% expression of MSC surface markers (CD73, CD90, CD105) and >90% post-thaw viability. [14]

Bone marrow–derived MSCs (autologous)

Harvested from the patient's own iliac crest, these cells have the advantage of being autologous — eliminating any theoretical risk of immune rejection. The disadvantages include: variable cell quality (declining with patient age — many rotator cuff patients are over 55), the need for an additional bone marrow aspiration procedure, and a processing delay between harvest and administration. Some surgeons favour combining bone marrow concentrate (which contains MSCs along with platelets and growth factors) with the repair construct at the time of surgery.

The choice between allogeneic and autologous MSCs should be made on a case-by-case basis, considering the patient's age, tear characteristics, and preference. In the available clinical literature, both approaches have shown promising results, and no head-to-head comparison exists specifically for rotator cuff repair.

Limitations and honest perspective

It is important to state plainly what MSC therapy for rotator cuff tears is — and is not:

Frequently asked questions

Can MSC therapy heal a full-thickness rotator cuff tear without surgery?

For a small, minimally retracted full-thickness tear in a patient who is not a surgical candidate, MSC injection may support biological healing and symptom improvement. However, for a retracted tear — where the tendon has pulled away from the bone — the gap must be closed mechanically. MSCs cannot bridge a physical gap. In these cases, MSC therapy is best considered as an adjunct at the time of surgical repair.

How soon after a rotator cuff tear can MSC therapy be administered?

There is no single answer. For acute traumatic tears in young patients, early surgical repair is generally recommended. For degenerative tears that have been present for weeks or months, MSC therapy can be considered at any point — though earlier intervention (before significant muscle atrophy develops) is likely to yield better results. Many clinicians recommend completing a 6–12 week trial of conservative management (physiotherapy, activity modification) before proceeding to MSC therapy, as a proportion of partial tears will improve without intervention.

Is MSC therapy covered by insurance?

In most jurisdictions, MSC therapy for rotator cuff pathology is considered elective and investigational, and is not covered by standard health insurance. Patients should expect to pay out of pocket. Costs vary significantly between clinics and countries. At VELAR Center, a detailed cost breakdown is provided during the consultation, and no patient proceeds to treatment without a clear understanding of the financial commitment.

What is the re-tear rate after MSC-augmented rotator cuff repair?

The available evidence suggests that MSC augmentation may reduce re-tear rates compared to repair alone. In the meta-analysis cited above, the pooled re-tear rate was approximately 13% in the MSC-augmented group versus 40% in the control group at 12 months. However, these figures come from small studies with selected patient populations and should be interpreted cautiously. Re-tear rates depend heavily on tear size, patient age, and rehabilitation quality — MSC therapy is one factor among many.

References

  1. Yamamoto A, Takagishi K, Osawa T, et al. Prevalence and risk factors of a rotator cuff tear in the general population. Journal of Shoulder and Elbow Surgery. 2010;19(1):116-120. doi:10.1016/j.jse.2009.04.006 ↩
  2. Galatz LM, Ball CM, Teefey SA, et al. The outcome and repair integrity of completely arthroscopically repaired large and massive rotator cuff tears. Journal of Bone and Joint Surgery. 2004;86(2):219-224. doi:10.2106/00004623-200402000-00002 ↩
  3. Le BTN, Wu XL, Lam PH, Murrell GAC. Factors predicting rotator cuff retears: an analysis of 1000 consecutive rotator cuff repairs. American Journal of Sports Medicine. 2014;42(5):1134-1142. doi:10.1177/0363546514525336 ↩
  4. Benjamin M, McGonagle D. Entheses: tendon and ligament attachment sites. Scandinavian Journal of Medicine & Science in Sports. 2009;19(4):520-527. doi:10.1111/j.1600-0838.2009.00906.x ↩
  5. Hernigou P, Flouzat Lachaniette CH, Delambre J, et al. Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study. International Orthopaedics. 2014;38(9):1811-1818. doi:10.1007/s00264-014-2391-1 ↩
  6. Tashjian RZ. Epidemiology, natural history, and indications for treatment of rotator cuff tears. Clinics in Sports Medicine. 2012;31(4):589-604. doi:10.1016/j.csm.2012.07.001 ↩
  7. Proffen BL, Shakir S, Bifani J, et al. The effect of mesenchymal stromal cell sheets on the inflammatory stage of flexor tendon healing. Stem Cell Research & Therapy. 2016;7:144. doi:10.1186/s13287-016-0401-2 ↩
  8. Gulotta LV, Kovacevic D, Packer JD, et al. Bone marrow-derived mesenchymal stem cells transduced with scleraxis improve rotator cuff healing in a rat model. American Journal of Sports Medicine. 2011;39(6):1282-1289. doi:10.1177/0363546510395485 ↩
  9. Chen P, Cui L, Chen GC, et al. The application of BMP-12-overexpressing mesenchymal stem cells loaded on a collagen scaffold for rotator cuff repair in a rabbit model. Journal of Shoulder and Elbow Surgery. 2020;29(3):e90-e103. doi:10.1016/j.jse.2019.06.022 ↩
  10. Shapiro E, Grande D, Drakos M. Biologics in Achilles tendon healing and repair: a review. Current Reviews in Musculoskeletal Medicine. 2015;8(1):9-17. doi:10.1007/s12178-015-9257-z ↩
  11. Kim YS, Sung CH, Chung SH, et al. Does an injection of adipose-derived mesenchymal stem cells loaded in fibrin glue influence rotator cuff repair outcomes? A clinical and magnetic resonance imaging study. American Journal of Sports Medicine. 2020;48(8):1889-1898. doi:10.1177/0363546520917963 ↩
  12. Liu Y, Li Z, Li J, et al. Mesenchymal stem cell therapy for rotator cuff repair: a systematic review and meta-analysis. Orthopaedic Journal of Sports Medicine. 2022;10(4):23259671221087358. doi:10.1177/23259671221087358 ↩
  13. Jo CH, Chai JW, Jeong EC, et al. Intratendinous injection of mesenchymal stem cells for the treatment of rotator cuff disease: a 2-year follow-up study. Arthroscopy. 2021;37(3):858-868. doi:10.1016/j.arthro.2020.10.036 ↩
  14. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  15. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩